Education
About Us
Working with TipRanks
Follow Us
Cullinan Management, Inc. (CGEM)
:CGEM
CGEM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.27 - $30.19
Previous CloseN/A
Volume73.34K
Average Volume (3M)433.00K
Market Cap
$438.85M
Enterprise Value$316.68M
Total Cash (Recent Filing)$83.00M
Total Debt (Recent Filing)$2.15M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
May 20, 2025EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.13
Shares Outstanding58,512,825
10 Day Avg. Volume428,402
30 Day Avg. Volume433,001
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)936.21
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.02K
Enterprise Value/Ebitda-1.61
Forecast
1Y Price Target
$32.71Price Target Upside318.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Cullinan Management News
---
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company holds approximately $607 million in cash and investments, with a cash runway expected into 2028.
Pipeline DevelopmentCullinan remains focused on the development of CLN-978 in systemic lupus erythematosus and rheumatoid arthritis, expecting initial data from trials in 2025.
Regulatory ProgressCullinan plans to submit for U.S. regulatory approval in 2H25, following the positive results from the REZILIENT1 study.
Bears Say
Market CompetitionThe scarcity value of Cullinan's CD19xCD3 TCE is maintained, positioning the company uniquely in the market.
Regulatory ChallengesPending discussions with the FDA, CGEM and partner Taiho Oncology plan to file a regulatory submission in 2H25.
---
Ownership Overview
6.96% Insiders
12.29% Mutual Funds
0.28% Other Institutional Investors
65.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CGEM FAQ
What was Cullinan Management, Inc.’s price range in the past 12 months?
Cullinan Management, Inc. lowest stock price was $7.27 and its highest was $30.19 in the past 12 months.
What is Cullinan Management, Inc.’s market cap?
Cullinan Management, Inc.’s market cap is $438.85M.
When is Cullinan Management, Inc.’s upcoming earnings report date?
Cullinan Management, Inc.’s upcoming earnings report date is May 20, 2025 which is in 46 days.
How were Cullinan Management, Inc.’s earnings last quarter?
Cullinan Management, Inc. released its earnings results on Feb 27, 2025. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.75 by $0.02.
Is Cullinan Management, Inc. overvalued?
According to Wall Street analysts Cullinan Management, Inc.’s price is currently Undervalued.
Does Cullinan Management, Inc. pay dividends?
Cullinan Management, Inc. does not currently pay dividends.
What is Cullinan Management, Inc.’s EPS estimate?
Cullinan Management, Inc.’s EPS estimate is -0.82.
How many shares outstanding does Cullinan Management, Inc. have?
Cullinan Management, Inc. has 58,512,825 shares outstanding.
What happened to Cullinan Management, Inc.’s price movement after its last earnings report?
Cullinan Management, Inc. reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.75. Following the earnings report the stock price went up 1.893%.
Which hedge fund is a major shareholder of Cullinan Management, Inc.?
Currently, no hedge funds are holding shares in CGEM
---
Cullinan Management Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.71 (318.29% Upside)
$32.71 (318.29% Upside)
Blogger Sentiment
Bullish
CGEM Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 281.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $212.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 11.7%
Last 30 Days ▼ 11.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.97%
12-Months-Change
Fundamentals
Return on Equity
-32.06%
Trailing 12-Months
Asset Growth
28.31%
Trailing 12-Months
Company Description
Cullinan Management, Inc.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
---
CGEM Stock 12 Month Forecast
Average Price Target
$32.71
▲(318.29% Upside)
Technical Analysis
Editas Medicine
―
Crispr Therapeutics AG
―
Kiniksa Pharmaceuticals
―
Allogene Therapeutics
―
Foghorn Therapeutics
―
Best Analysts Covering CGEM
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
+27.40%
assigned a buy rating 10 months ago
Copying Kaveri Pohlman's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +27.40% per trade.
---